Xeptiva Therapeutics is a technology company.
Xeptiva Therapeutics has raised $3.0M across 1 funding round.
Xeptiva Therapeutics has raised $3.0M in total across 1 funding round.
Xeptiva Therapeutics is a USA-based biotechnology startup, founded in 2021, specializing in novel therapeutic vaccines for companion animals to address chronic conditions like neuroinflammation, chronic pain, atopic dermatitis, and osteoarthritis in dogs.[1][2][3][4] The company serves pet owners and veterinarians by developing affordable, effective immunotherapies that improve pets' quality of life and lifespan, with 5 products in its pipeline and ongoing clinical studies for leading candidates.[1][2] Recent growth includes producing its first GMP-quality industrial batch for clinical trials and closing a $2.5 million investment round in August to fund regulatory approvals and international expansion into Latin America and the US.[4]
Xeptiva Therapeutics emerged from over a decade of research in chronic neuroinflammation, led by founders Emiliano Trías, Luis Barbeito, and CEO Josefina Correa, who formalized the company in early 2021.[1][4] Trías and Barbeito, scientists with deep expertise in neurogenic inflammation, aging, and chronic conditions, drove the initial R&D, culminating in therapeutic vaccines for veterinary use after years at institutions like the Institut Pasteur of Montevideo.[4] A pivotal moment came with the production of their first GMP-quality vaccine batch for dog osteoarthritis trials, enabling regulatory pursuits and highlighting Uruguay's biotech ecosystem support.[4]
Xeptiva rides the wave of veterinary biotech innovation, fueled by rising pet humanization trends where owners spend more on advanced treatments for chronic diseases in an aging companion animal population.[2][4] Timing aligns with post-pandemic growth in animal health markets, projected to expand globally, amplified by Uruguay's strengthening life sciences ecosystem that supports startups like Xeptiva through talent and infrastructure.[4] Market forces favoring affordable immunotherapies over repeated drugs work in its favor, while its success—via local investments and international ambitions—inspires regional biotech collaboration and elevates veterinary care standards.[4]
Xeptiva is poised for regulatory breakthroughs in 2026, with trials advancing osteoarthritis and dermatitis vaccines, followed by launches in Latin America and the US to capture a slice of the booming $50B+ veterinary therapeutics market.[4] Trends like personalized pet medicine and immunotherapy adoption will propel growth, potentially drawing more funding as it scales manufacturing. Its influence may evolve from niche innovator to global player, transforming chronic pet care much like human biotech has for inflammation disorders—building on its research roots to deliver lasting animal health impact.[1][4]
Xeptiva Therapeutics has raised $3.0M in total across 1 funding round.
Xeptiva Therapeutics's investors include Pedro Arnt.
Xeptiva Therapeutics has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $3.0M Seed | Pedro Arnt |